Abstract
Background
Giant cell tumor (GCT) of the bone is known for its locally aggressive behavior and tendency to recur. It is an admixture of rounded or spindle-shaped mononuclear neoplastic stromal cells and multinucleated osteoclast-like giant cells with their proportionate dispersion among the former. Zoledronic acid (a bisphosphonate) is being used in various cancers such as myelomas and metastasis, for osteoporosis with an aim to reduce the resorption of bone, and as an adjuvant treatment for the management of GCT of bone for reduction of local recurrence. We have carried out a prospective comparative study to assess the effect of intravenous infusion of zoledronic acid on histopathology and recurrence of GCT of bone.
Materials and Methods
The study was carried out in the biopsy proven GCTs in 37 patients; 15 males and 22 females, in the age range from 17 to 55 years. They were treated with extended curettage. Of these 37 patients, 18 were given three doses of 4 mg zoledronic acid infusion at 3-week intervals and extended curettage was performed 2 weeks after the last infusion whereas the other 19 were treated with extended curettage without zoledronic infusion. The post infusion histopathology of the curetted material was compared with the histopathology of initial biopsy. All the patients were evaluated at 3-month intervals for the first 2 years and then six monthly thereafter, for local recurrence and functional outcome of limb using the Musculoskeletal Tumor Society (MSTS) score.
Results
In postzoledronic infusion cases, the histopathology of samples showed abnormal stromal cells secreting matrix leading to fibrosis and calcification. The type of fibrosis and calcification was different from pathological calcification and fibrosis what is usually observed. There was a good marginalization and solidification of tumors which made surgical curettage easier in six cases in the study group. There was noticeable reduction in the number of giant cells and alteration in morphology of stromal cells to the fibroblastic-fibrocytic series type in comparison to preinfusion histopathology. Recurrence occurred in one case out of 18 patients in infusion group whereas in four cases among 19 patients in control group. The functional results were assessed, and the overall average MSTS score was 27.50 (range 24–30) and 27.00 (range 23.50–30) in the study and control groups, respectively.
Conclusions
We observed that bisphosphonates reduce osteoclast activity and affects stromal cells in GCT, resulting in the reduction of their numbers and noticeable apoptosis. This results in better marginalization of the lesions and reduced recurrence. Extended curettage of friable GCT became easier and adequate which otherwise might not have been possible.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Camesale PG. General principles of tumors. In: Crensaw AH, editor. Campbell’s Operative Orthopedics. Missouri: Mosby Year Book; 1992. p. 195–234.
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987;69:106–14.
Athanasou NA, Bansal M, Forsyth R, Reid RR, Sapi Z. Giant cell tumour of bone. In: Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F, editors. World Health Organization - Classification of Tumors of Soft Tissue and Bone. Lyon: IARC Press: 2013. p. 321–4.
Szendröi M. Giant-cell tumour of bone. J Bone Joint Surg Br 2004;86:5–12.
Wysocki RW, Soni E, Virkus WW, Scarborough MT, Leurgans SE, Gitelis S, et al. Is intralesional treatment of giant cell tumor of the distal radius comparable to resection with respect to local control and functional outcome? Clin Orthop Relat Res 2015;473:706–15.
Gitelis S, Mallin BA, Piasecki R Turner F. Intralesional excision compared with en bloc resection for giant-cell tumors of bone. J Bone Joint Surg Am 1993;75:1648–55.
Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS, et al. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999;81:811–20.
Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am 2006;37:35–51.
Ural AU, Yilmaz MI, Avcu F, Pekel A, Zerman M, Nevruz O, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003;78:443–9.
Chang SS, Suratwala SJ, Jung KM, Doppelt JD, Zhang HZ, Blaine TA, et al. Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res 2004; 426103–9.
Fujimoto N, Nakagawa K, Seichi A, Terahara A, Tago M, Aoki Y, et al. A new bisphosphonate treatment option for giant cell tumors. Oncol Rep 2001;8:643–7.
Lau CR, Wong KC, Huang L, Li G, Tsui SK, Kumta SM, et al. A mouse model of luciferase-transfected stromal cells of giant cell tumor of bone. Connect Tissue Res 2015;56:493–503.
Lau CP, Huang L, Wong KC, Kumta SM. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone. Connect Tissue Res 2013;54:439–49.
Lau CR Huang L, Tsui SK, Ng PK, Leung PY, Kumta SM, et al. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone. J Orthop Res 2011;29:403–13.
Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF, et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study. Bone 2008;42:68–73.
Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM, et al. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004;75:71–7.
Cheng YY, Huang L, Kumta SM, Lee KM, Lai FM, Tam JS, et al. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration. Ultrastruct Pathol 2003;27:385–91.
Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005;36:945–54.
Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial – The zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003;21:3150–7.
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Recurrent giant cell tumor of long bones: Analysis of surgical management. Clin Orthop Relat Res 2011;469:1181–7.
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: Risk factors for recurrence. Clin Orthop Relat Res 2011;469:591–9.
Xu HR Niu XH, Zhang Q, Hao L, Ding Y, Li Y, et al. Subchondral bone grafting reduces degenerative change of knee joint in patients of giant cell tumor of bone. Chin Med J (Engl) 2013;126:3053–6.
Vult von Steyern F, Bauer HC, Trovik C, Kivioja A, Bergh P. Holmberg Jörgensen P, et al. Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian sarcoma group study. J Bone Joint Surg Br 2006;88:531–5.
Arpornchayanon O, Leerapun T. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: A case report and review of the literature. J Med Assoc Thai 2008;91:1609–12.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kundu, Z.S., Sen, R., Dhiman, A. et al. Effect of Intravenous Zoledronic Acid on Histopathology and Recurrence after Extended Curettage in Giant Cell Tumors of Bone: A Comparative Prospective Study. IJOO 52, 45–50 (2018). https://doi.org/10.4103/ortho.IJOrtho_216_17
Published:
Issue Date:
DOI: https://doi.org/10.4103/ortho.IJOrtho_216_17